

Table 1: Baseline Characteristics of Cases 1-4

	Case 1	Case 2	Case 3	Case 4
Age(yrs)	65	69	62	74
Gender(M/F)	M	M	M	F
HbA1C (%)	11.4	6.1	13	7.8
Duration of T2D(yrs)	6	7	4	8
Weight in Kgs	102.5	90	87.1	71.6
BMI	33.37	26.9	28.34	27.95
BP(mm Hg)	126/80	132/64	148/78	98/60
PR(bpm)	78	60	82	86
HTN(Y/N)	Y	N	Y	Y
Dyslipidemia(Y/N)	Y	N	Y	Y
ACE/ARB (Daily Dose)	Valsartan (80mg)	-	Losartan (100mg)	Losartan (100mg)
Statin((Daily Dose)	Rosuvastatin (40mg)	-	Atorvastatin (20mg)	Rosuvastatin (40mg)
GLP-1RA (Weekly Dose)	Dulaglutide (1.5mg)	Dulaglutide (0.75mg)	Dulaglutide (1.5mg)	Dulaglutide (1.5mg)
Basal Insulin(Y/N)	Y	N	Y	Y
Prandial Insulin(Y/N)	Y	N	Y	Y
TZD (Y/N)	Y	N	N	N
NIH Staging CKD	Stage 4	Stage 4	Stage 4	Stage 4
KDIGO Staging	G4A3	G4A3	G4A3	G4A3
Baseline UACR (mg/g)	2000	1253	1065	527
Baseline C02(mmol/L) (20-30mmol/L)	23	25	28	24
SGLT-2 Inhibitor (Daily dose)	Empagliflozin (10mg)	Dapagliflozin (5mg)	Ertugliflozin (15mg)	Empagliflozin (10mg)
Duration of follow up on SGLT-2 Inhibitor(months)	30	6	9	15

BP: Blood Pressure; PR: Pulse Rate; ACEI/ARB: Angiotensin-converting enzyme inhibitors/Angiotensin II Receptor Blocker ; HTN: Hypertension; GLP-1RA: Glucagon Like Peptide 1 Receptor Agonist; TZD: Thiazolidinediones; NIH: National Institute of Health; KDIGO: Kidney Disease Outcome Quality Initiative; UACR: Urin Albumin to Creatinine Ratio; SGLT-2 Inhibitor: Sodium-glucose Cotransporter-2 inhibitor